Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 275

1.

Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma.

Yancovitz M, Litterman A, Yoon J, Ng E, Shapiro RL, Berman RS, Pavlick AC, Darvishian F, Christos P, Mazumdar M, Osman I, Polsky D.

PLoS One. 2012;7(1):e29336. doi: 10.1371/journal.pone.0029336. Epub 2012 Jan 3.

2.

Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.

Satzger I, Marks L, Kerick M, Klages S, Berking C, Herbst R, Völker B, Schacht V, Timmermann B, Gutzmer R.

Oncotarget. 2015 Nov 10;6(35):37895-905. doi: 10.18632/oncotarget.5634.

3.

Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.

Busam KJ, Hedvat C, Pulitzer M, von Deimling A, Jungbluth AA.

Am J Surg Pathol. 2013 Mar;37(3):413-20. doi: 10.1097/PAS.0b013e318271249e.

PMID:
23211290
4.

Comparing BRAF mutation status in matched primary and metastatic cutaneous melanomas: implications on optimized targeted therapy.

Saroufim M, Habib RH, Gerges R, Saab J, Loya A, Amr SS, Sheikh S, Satti M, Oberkanins C, Khalifeh I.

Exp Mol Pathol. 2014 Dec;97(3):315-20. doi: 10.1016/j.yexmp.2014.09.008. Epub 2014 Sep 16.

PMID:
25236573
5.

Comparative study on driver mutations in primary and metastatic melanomas at a single Japanese institute: A clue for intra- and inter-tumor heterogeneity.

Kaji T, Yamasaki O, Takata M, Otsuka M, Hamada T, Morizane S, Asagoe K, Yanai H, Hirai Y, Umemura H, Iwatsuki K.

J Dermatol Sci. 2017 Jan;85(1):51-57. doi: 10.1016/j.jdermsci.2016.10.006. Epub 2016 Oct 13.

PMID:
27771229
6.

Molecular platforms utilized to detect BRAF V600E mutation in melanoma.

Curry JL, Torres-Cabala CA, Tetzlaff MT, Bowman C, Prieto VG.

Semin Cutan Med Surg. 2012 Dec;31(4):267-73. doi: 10.1016/j.sder.2012.07.007.

PMID:
23174497
7.

Lymph node metastases of melanoma: challenges for BRAF mutation detection.

Chen G, Dudley J, Tseng LH, Smith K, Gurda GT, Gocke CD, Eshleman JR, Lin MT.

Hum Pathol. 2015 Jan;46(1):113-9. doi: 10.1016/j.humpath.2014.09.014. Epub 2014 Oct 7.

PMID:
25456393
8.

Quantitative analysis of the BRAF V600E mutation in circulating tumor-derived DNA in melanoma patients using competitive allele-specific TaqMan PCR.

Ashida A, Sakaizawa K, Mikoshiba A, Uhara H, Okuyama R.

Int J Clin Oncol. 2016 Oct;21(5):981-988. Epub 2016 Apr 4.

PMID:
27041702
9.

Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.

Long GV, Wilmott JS, Capper D, Preusser M, Zhang YE, Thompson JF, Kefford RF, von Deimling A, Scolyer RA.

Am J Surg Pathol. 2013 Jan;37(1):61-5. doi: 10.1097/PAS.0b013e31826485c0.

PMID:
23026937
10.

A comparison of immunohistochemical and molecular methods used for analyzing the BRAF V600E gene mutation in malignant melanoma in Taiwan.

Huang WK, Kuo TT, Wu CE, Cheng HY, Hsieh CH, Hsieh JJ, Shen YC, Hou MM, Hsu T, Chang JW.

Asia Pac J Clin Oncol. 2016 Dec;12(4):403-408. doi: 10.1111/ajco.12574. Epub 2016 Aug 4.

PMID:
27488807
11.

Tumor cellularity as a quality assurance measure for accurate clinical detection of BRAF mutations in melanoma.

Dudley JC, Gurda GT, Tseng LH, Anderson DA, Chen G, Taube JM, Gocke CD, Eshleman JR, Lin MT.

Mol Diagn Ther. 2014 Aug;18(4):409-18. doi: 10.1007/s40291-014-0091-6.

12.

BRAF-V600 Mutation Heterogeneity in Primary and Metastatic Melanoma: A Study With Pyrosequencing and Immunohistochemistry.

Yaman B, Kandiloğlu G, Akalin T.

Am J Dermatopathol. 2016 Feb;38(2):113-20. doi: 10.1097/DAD.0000000000000404.

PMID:
26630683
13.

Low incidence of minor BRAF V600 mutation-positive subclones in primary and metastatic melanoma determined by sensitive and quantitative real-time PCR.

Kristensen T, Clemmensen O, Hoejberg L.

J Mol Diagn. 2013 May;15(3):355-61. doi: 10.1016/j.jmoldx.2012.12.003. Epub 2013 Mar 13.

PMID:
23499336
14.

Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma.

Anderson S, Bloom KJ, Vallera DU, Rueschoff J, Meldrum C, Schilling R, Kovach B, Lee JR, Ochoa P, Langland R, Halait H, Lawrence HJ, Dugan MC.

Arch Pathol Lab Med. 2012 Nov;136(11):1385-91. doi: 10.5858/arpa.2011-0505-OA. Epub 2012 Feb 14.

PMID:
22332713
15.

Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing.

Colomba E, Hélias-Rodzewicz Z, Von Deimling A, Marin C, Terrones N, Pechaud D, Surel S, Côté JF, Peschaud F, Capper D, Blons H, Zimmermann U, Clerici T, Saiag P, Emile JF.

J Mol Diagn. 2013 Jan;15(1):94-100. doi: 10.1016/j.jmoldx.2012.09.001. Epub 2012 Nov 15.

PMID:
23159108
16.

NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.

Uguen A, Talagas M, Costa S, Samaison L, Paule L, Alavi Z, De Braekeleer M, Le Marechal C, Marcorelles P.

Diagn Pathol. 2015 Jul 25;10:121. doi: 10.1186/s13000-015-0359-0.

17.

Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.

Willmore-Payne C, Holden JA, Tripp S, Layfield LJ.

Hum Pathol. 2005 May;36(5):486-93.

PMID:
15948115
18.

Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: a systematic review and meta-analysis of current published literature.

Anwar MA, Murad F, Dawson E, Abd Elmageed ZY, Tsumagari K, Kandil E.

J Surg Res. 2016 Jun 15;203(2):407-15. doi: 10.1016/j.jss.2016.04.029. Epub 2016 Apr 23. Review.

PMID:
27363650
19.

High-sensitivity PCR method for detecting BRAF V600E mutations in metastatic colorectal cancer using LNA/DNA chimeras to block wild-type alleles.

Chen D, Huang JF, Xia H, Duan GJ, Chuai ZR, Yang Z, Fu WL, Huang Q.

Anal Bioanal Chem. 2014 Apr;406(9-10):2477-87. doi: 10.1007/s00216-014-7618-x. Epub 2014 Feb 6.

PMID:
24500755
20.

Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma.

Menzies AM, Haydu LE, Visintin L, Carlino MS, Howle JR, Thompson JF, Kefford RF, Scolyer RA, Long GV.

Clin Cancer Res. 2012 Jun 15;18(12):3242-9. doi: 10.1158/1078-0432.CCR-12-0052. Epub 2012 Apr 24.

Supplemental Content

Support Center